Zunbo He
Overview
Explore the profile of Zunbo He including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
6
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu B, Liu Y, Zhang T, He Z, Zhou J
Expert Opin Drug Metab Toxicol
. 2025 Jan;
:1-10.
PMID: 39838812
Introduction: Ertugliflozin is the fourth sodium-glucose co-transporter (SGLT2) inhibitor approved by the US FDA in 2017 for the treatment of type 2 diabetes mellitus. Areas Covered: The main purpose of...
2.
Xu B, Zhang T, Kang B, Yang X, Li S, Chen J, et al.
Cardiovasc Drugs Ther
. 2024 Dec;
PMID: 39630411
Purpose: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been reported to exhibit antiarrhythmic effects. However, there is conflicting evidence regarding the association between SGLT2 inhibitors and ventricular arrhythmias or sudden cardiac...
3.
Zhang T, Xu B, Tang F, He Z, Zhou J
Expert Rev Clin Pharmacol
. 2024 Oct;
17(11):999-1008.
PMID: 39412085
Introduction: Pediatric low-grade glioma (pLGG) is the most prevalent childhood brain tumor group, currently regarded as a chronic disease. On 23 April 2024, the U.S. FDA approved a new type...
4.
Xu B, Kang B, Tang F, Zhou J, He Z
Expert Rev Clin Pharmacol
. 2024 Aug;
:1-9.
PMID: 39206790
Introduction: Lowering blood glucose is important to prevent long-term microvascular complications in adults with type 2 diabetes mellitus (T2DM). Various evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors are beneficial...
5.
Xu B, Li S, Kang B, Fan S, Chen C, Li W, et al.
Mol Biol Rep
. 2023 Oct;
50(11):9637-9647.
PMID: 37819499
Type 2 diabetes mellitus (T2DM) is a complex metabolic disease characterized by hyperglycaemia. T2DM is a highly heterogeneous polygenic disease. Due to genetic variation, variations in lifestyle and other environmental...
6.
Xu B, Li S, Kang B, Fan S, He Z, Zhou J
Invest New Drugs
. 2022 Sep;
40(6):1333-1341.
PMID: 36074313
Classic Hodgkin lymphoma (cHL) accounts for more than 90% of HL in developed countries. Although the current combined modality therapy make it have a high cure rate, the prognosis for...
7.
Li S, Xu B, Fan S, Kang B, Deng L, Chen D, et al.
Expert Rev Clin Pharmacol
. 2022 Sep;
15(9):1107-1117.
PMID: 36065506
Introduction: Metformin has been recognized as the first-choice drug for type 2 diabetes mellitus (T2DM). The potency of metformin in the treatment of type 2 diabetes has always been in...